Screener
Arcus Biosciences RCUS Deferred Revenue
Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by Arcus Biosciences in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityCurrent.
The source filing: Arcus Biosciences’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001724521-26-000044
FAQ
- What is Arcus Biosciences's deferred revenue?
- Arcus Biosciences (RCUS) reported deferred revenue of $19M in Q2 2026.
- How has Arcus Biosciences's deferred revenue changed year-over-year?
- Arcus Biosciences's deferred revenue decreased by 73.2% year-over-year, from $71M to $19M.
- What is the long-term trend for Arcus Biosciences's deferred revenue?
- Over 5 years (2020 to 2025), Arcus Biosciences's deferred revenue has grown at a -14.0% compound annual growth rate (CAGR), from $74.57M to $35M.
- What does deferred revenue mean?
- Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.
Ask your AI about Arcus Biosciences's deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude